Jack Phillips - 22 Jun 2022 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)

Role
Chief Executive Officer
Signature
/s/ Steven Reichling, attorney-in-fact
Issuer symbol
AXDX
Transactions as of
22 Jun 2022
Transactions value $
-$25,660
Form type
4
Filing time
24 Jun 2022, 16:14:15 UTC
Previous filing
28 Apr 2022
Next filing
17 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXDX Common Stock Options Exercise $0 +62.2K +29.87% $0.00 270K 22 Jun 2022 Direct F1
transaction AXDX Common Stock Sale -$25.7K -28.2K -10.43% $0.91* 242K 22 Jun 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXDX Employee Restricted Stock Units Options Exercise $0 -62.2K -50% $0.00 62.2K 22 Jun 2022 Common Stock 62.2K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2 The reporting person received restricted stock units, of which vests in equal annual amounts on each anniversary of the grant date over three years, beginning on June 22, 2021 and ending on June 22, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.